Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

90Y Ibritumomab Tiuxetan

90Y Ibritumomab Tiuxetan Am J Cancer 2002; 1 (5): 349 GUEST COMMENTARIES 1175-6357/02/0005-0349/$25.00/0 © Adis International Limited. All rights reserved. coated CD20+ cells. However, although Y does not emit γ Y Ibritumomab Tiuxetan A Viewpoint by Nozomi Niitsu radiation, therefore, making radiation exposure to healthcare per- sonnel minimal, a multidisciplinary team approach is needed to Kitasato University School of Medicine, Kitasato, Sagamihara, Kanagawa, Japan safely and effectively provide radioimmunotherapy. 90 90 In clinical trials, the ibritumomab tiuxetan therapeutic regi- Yttrium ( Y) Ibritumomab tiuxetan is a radiolabeled mole- men has demonstrated an impressive response rate in relapsed or cule composed of a murine immunoglobulin G1 monoclonal anti- chemorefractory indolent lymphomas. In a randomized trial, the CD20 antibody covalently bound to the chelator tiuxetan, which 90 regimen produced substantially higher overall and complete re- links the isotope Y. The CD20 antigen, the target of ibritumo- sponse rates than those obtained by rituximab. However, advan- mab, is a 35 kDa phosphoprotein present on the majority of nor- tages in overall and progression-free survival have not been dem- mal and neoplastic B lymphocytes. onstrated, to date. The toxicity of the ibritumomab tiuxetan Reasons supporting the use of radiolabeled antibodies for the therapeutic regimen is primarily http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png American Journal of Cancer Springer Journals

90Y Ibritumomab Tiuxetan

American Journal of Cancer , Volume 1 (5) – Aug 10, 2012

90Y Ibritumomab Tiuxetan

Abstract

Am J Cancer 2002; 1 (5): 349 GUEST COMMENTARIES 1175-6357/02/0005-0349/$25.00/0 © Adis International Limited. All rights reserved. coated CD20+ cells. However, although Y does not emit γ Y Ibritumomab Tiuxetan A Viewpoint by Nozomi Niitsu radiation, therefore, making radiation exposure to healthcare per- sonnel minimal, a multidisciplinary team approach is needed to Kitasato University School of Medicine, Kitasato, Sagamihara, Kanagawa, Japan safely and effectively provide...
Loading next page...
 
/lp/springer-journals/90y-ibritumomab-tiuxetan-rHPJbCncep
Publisher
Springer Journals
Copyright
Copyright © 2002 by Adis International Limited
Subject
Pharmacy; Pharmacy
ISSN
1175-6357
DOI
10.2165/00024669-200201050-00006
Publisher site
See Article on Publisher Site

Abstract

Am J Cancer 2002; 1 (5): 349 GUEST COMMENTARIES 1175-6357/02/0005-0349/$25.00/0 © Adis International Limited. All rights reserved. coated CD20+ cells. However, although Y does not emit γ Y Ibritumomab Tiuxetan A Viewpoint by Nozomi Niitsu radiation, therefore, making radiation exposure to healthcare per- sonnel minimal, a multidisciplinary team approach is needed to Kitasato University School of Medicine, Kitasato, Sagamihara, Kanagawa, Japan safely and effectively provide radioimmunotherapy. 90 90 In clinical trials, the ibritumomab tiuxetan therapeutic regi- Yttrium ( Y) Ibritumomab tiuxetan is a radiolabeled mole- men has demonstrated an impressive response rate in relapsed or cule composed of a murine immunoglobulin G1 monoclonal anti- chemorefractory indolent lymphomas. In a randomized trial, the CD20 antibody covalently bound to the chelator tiuxetan, which 90 regimen produced substantially higher overall and complete re- links the isotope Y. The CD20 antigen, the target of ibritumo- sponse rates than those obtained by rituximab. However, advan- mab, is a 35 kDa phosphoprotein present on the majority of nor- tages in overall and progression-free survival have not been dem- mal and neoplastic B lymphocytes. onstrated, to date. The toxicity of the ibritumomab tiuxetan Reasons supporting the use of radiolabeled antibodies for the therapeutic regimen is primarily

Journal

American Journal of CancerSpringer Journals

Published: Aug 10, 2012

There are no references for this article.